BRIEF published on 12/16/2025 at 21:23, 6 months 1 day ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
BRIEF published on 12/16/2025 at 21:23, 6 months 1 day ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 6 months 1 day ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 6 months 12 days ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 6 months 12 days ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 6 months 22 days ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 6 months 22 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 7 months 5 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 7 months 27 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 7 months 27 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
Published on 06/18/2026 at 00:00, 3 hours 31 minutes ago LIR Life Sciences Completes Comparative Animal Study Showing Successful Protamine-Enhanced Permeation Transport of Both Semaglutide and Tirzepatide
Published on 06/17/2026 at 23:30, 4 hours 1 minute ago Polaris Renewable Energy Announces Postponement of Annual Meeting of Shareholders
Published on 06/17/2026 at 22:50, 4 hours 41 minutes ago International Battery Metals Ltd. Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results
Published on 06/17/2026 at 22:30, 5 hours 1 minute ago Innodata Appoints Jayant Chauhan as Chief Financial Officer
Published on 06/17/2026 at 16:55, 10 hours 36 minutes ago Snipp Interactive Named a Representative Vendor in the Gartner(R) 2026 Market Guide for Loyalty Program Vendors
Published on 06/18/2026 at 02:45, 46 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Update on APAC matter
Published on 06/17/2026 at 21:40, 5 hours 51 minutes ago Tinnitus Quest Builds Momentum with Oxford Research Study, New Funding Call, and Second Tinnitus Hackathon
Published on 06/17/2026 at 19:10, 8 hours 21 minutes ago Africa Finance Corporation and Leading Italian Institutions Sign Strategic Cooperation Agreements at AFC-Italy Forum to Mobilise Capital and Accelerate Industrial Development Across Africa
Published on 06/17/2026 at 18:40, 8 hours 51 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 06/17/2026 at 18:36, 8 hours 55 minutes ago BILENDI: Bilendi announces that Euroland Corporate has initiated coverage of its shares
Published on 06/17/2026 at 17:40, 9 hours 51 minutes ago Report on share repurchases from 10 to 16 June 2026
Published on 06/17/2026 at 08:45, 18 hours 46 minutes ago Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 15 hours ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 2 days 4 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 2 days 8 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
